PriceTargets.com logo

Collegium Pharmaceutical - COLL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $47.00
  • Forecasted Upside: -3.35%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$48.63 As of 12/12/2025 05:00 PM ET
▲ +0.27 (0.56%)

This chart shows the closing price for COLL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Collegium Pharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for COLL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for COLL

Analyst Price Target is $47.00
▼ -3.35% Downside Potential
This price target is based on 7 analysts offering 12 month price targets for Collegium Pharmaceutical in the last 3 months. The average price target is $47.00, with a high forecast of $58.00 and a low forecast of $37.00. The average price target represents a -3.35% upside from the last price of $48.63.

This chart shows the closing price for COLL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Collegium Pharmaceutical. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/18/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/16/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/14/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/13/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/13/2025

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/8/2025BarclaysInitiated CoverageOverweight$58.00
12/8/2025Weiss RatingsUpgradeHold (C+) ➝ Buy (B-)
12/8/2025BarclaysInitiated CoverageOverweight$58.00
12/1/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
11/24/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
11/21/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
11/18/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
11/7/2025Truist FinancialBoost TargetBuy ➝ Buy$45.00 ➝ $48.00
11/7/2025HC WainwrightBoost TargetBuy ➝ Buy$44.00 ➝ $46.00
10/28/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$46.00
10/23/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
10/8/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
9/27/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
9/24/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
8/11/2025HC WainwrightUpgradeStrong-Buy$44.00
5/9/2025Piper SandlerReiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.00
4/9/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
3/24/2025HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
2/4/2025Piper SandlerLower TargetNeutral ➝ Neutral$37.00 ➝ $36.00
1/10/2025HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
1/10/2025Needham & Company LLCUpgradeHold ➝ Buy$46.00
10/11/2024Piper SandlerReiterated RatingNeutral ➝ Neutral$37.00 ➝ $37.00
9/5/2024HC WainwrightBoost TargetBuy ➝ Buy$47.00 ➝ $50.00
8/9/2024Truist FinancialBoost TargetBuy ➝ Buy$40.00 ➝ $42.00
8/9/2024Piper SandlerReiterated RatingNeutral ➝ Neutral$39.00 ➝ $37.00
8/9/2024Needham & Company LLCReiterated RatingHold
7/30/2024Needham & Company LLCReiterated RatingHold
7/30/2024HC WainwrightUpgradeNeutral ➝ Buy$47.00
6/7/2024Jefferies Financial GroupUpgradeHold ➝ Buy$41.00 ➝ $44.00
5/10/2024Needham & Company LLCDowngradeBuy ➝ Hold
5/10/2024Piper SandlerDowngradeOverweight ➝ Neutral$39.00 ➝ $39.00
4/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$40.00
2/26/2024Truist FinancialBoost TargetBuy ➝ Buy$37.00 ➝ $40.00
2/23/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$37.00 ➝ $39.00
2/2/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$40.00
1/4/2024Truist FinancialBoost TargetBuy ➝ Buy$31.00 ➝ $37.00
1/4/2024Needham & Company LLCBoost TargetBuy ➝ Buy$36.00 ➝ $40.00
1/4/2024Jefferies Financial GroupReiterated RatingBuy ➝ Hold$30.00 ➝ $37.00
8/25/2023Needham & Company LLCBoost TargetBuy ➝ Buy$35.00 ➝ $36.00
8/4/2023HC WainwrightReiterated RatingNeutral
8/4/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$35.00
4/25/2023Piper SandlerLower Target$37.00 ➝ $35.00
4/19/2023Needham & Company LLCReiterated RatingBuy$35.00
2/24/2023Needham & Company LLCReiterated RatingBuy$35.00
2/8/2023Needham & Company LLCReiterated RatingBuy$35.00
1/5/2023Needham & Company LLCBoost TargetBuy$34.00 ➝ $35.00
11/4/2022Needham & Company LLCLower TargetBuy$36.00 ➝ $34.00
8/15/2022HC WainwrightDowngradeNeutral
8/8/2022HC WainwrightDowngradeBuy ➝ Neutral
4/6/2022Needham & Company LLCBoost TargetBuy$34.00 ➝ $36.00
2/22/2022Piper SandlerBoost TargetOverweight$36.00 ➝ $42.00
2/15/2022Needham & Company LLCBoost TargetBuy$28.00 ➝ $34.00
2/15/2022HC WainwrightBoost TargetBuy$26.00 ➝ $29.00
2/15/2022Cantor FitzgeraldUpgradeNeutral ➝ Overweight$18.00 ➝ $26.00
11/15/2021Needham & Company LLCBoost TargetBuy$26.00 ➝ $28.00
11/5/2021HC WainwrightLower TargetBuy$28.00 ➝ $26.00
11/5/2021Needham & Company LLCLower TargetBuy$32.00 ➝ $26.00
9/17/2021Needham & Company LLCInitiated CoverageBuy$32.00
9/10/2021Needham & Company LLCInitiated CoverageBuy$32.00
8/27/2021Needham & Company LLCInitiated CoverageBuy$32.00
8/20/2021Needham & Company LLCInitiated CoverageBuy$32.00
8/6/2021Needham & Company LLCLower TargetBuy$34.00 ➝ $32.00
8/6/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral$30.00 ➝ $22.00
8/6/2021HC WainwrightLower TargetBuy$33.00 ➝ $28.00
7/16/2021Needham & Company LLCInitiated CoverageBuy$34.00
7/9/2021Needham & Company LLCInitiated CoverageBuy$34.00
7/2/2021Needham & Company LLCInitiated CoverageBuy$34.00
1/11/2021HC WainwrightBoost TargetBuy$29.00 ➝ $33.00
12/29/2020Needham & Company LLCReiterated RatingBuy ➝ Buy
(Data available from 12/13/2020 forward)

News Sentiment Rating

1.04 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 19 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/16/2025
  • 20 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/15/2025
  • 10 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/15/2025
  • 11 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/14/2025
  • 25 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/13/2025
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/13/2025
  • 14 very positive mentions
  • 30 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/12/2025
  • 18 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/12/2025

Current Sentiment

  • 18 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Collegium Pharmaceutical logo
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Read More

Today's Range

Now: $48.63
Low: $47.86
High: $48.97

50 Day Range

MA: $40.70
Low: $32.04
High: $48.86

52 Week Range

Now: $48.63
Low: $23.23
High: $49.15

Volume

369,386 shs

Average Volume

499,047 shs

Market Capitalization

$1.54 billion

P/E Ratio

30.20

Dividend Yield

N/A

Beta

0.61

Frequently Asked Questions

What sell-side analysts currently cover shares of Collegium Pharmaceutical?

The following Wall Street sell-side analysts have issued stock ratings on Collegium Pharmaceutical in the last year: Barclays PLC, HC Wainwright, Needham & Company LLC, Piper Sandler, Truist Financial Corporation, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for COLL.

What is the current price target for Collegium Pharmaceutical?

0 Wall Street analysts have set twelve-month price targets for Collegium Pharmaceutical in the last year. Their average twelve-month price target is $47.00, suggesting a possible downside of 3.4%. Barclays PLC has the highest price target set, predicting COLL will reach $58.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $37.00 for Collegium Pharmaceutical in the next year.
View the latest price targets for COLL.

What is the current consensus analyst rating for Collegium Pharmaceutical?

Collegium Pharmaceutical currently has 1 hold rating, 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe COLL will outperform the market and that investors should add to their positions of Collegium Pharmaceutical.
View the latest ratings for COLL.

What other companies compete with Collegium Pharmaceutical?

Other companies that are similar to Collegium Pharmaceutical include Protagonist Therapeutics, Cogent Biosciences, CRISPR Therapeutics, Apogee Therapeutics and Belite Bio. Learn More about companies similar to Collegium Pharmaceutical.

How do I contact Collegium Pharmaceutical's investor relations team?

Collegium Pharmaceutical's physical mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company's listed phone number is (781) 713-3699 and its investor relations email address is [email protected]. The official website for Collegium Pharmaceutical is www.collegiumpharma.com. Learn More about contacing Collegium Pharmaceutical investor relations.